Trending at Lumira Ventures

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

Alyssia Watkin Portfolio News, Thryv Therapeutics, Main Page

Montreal, Quebec – August 15, 2023 – Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced today FDA clearance of its Investigational New Drug application (IND) …

Cadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation Therapy

Alyssia Watkin Cadence Neuroscience, Portfolio News, Main Page

Cadence Neuroscience announced that it has secured $26 million in Series B financing. The round was led by Angelini Lumira Biosciences Fund (co-managed by Lumira Ventures and Angelini Ventures) and included other new investors F-Prime Capital, LivaNova USA, Angelini Ventures, Spectrum Financial Services, …

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO

Alyssia Watkin Portfolio News, Antiva Biosciences, Main Page

Proceeds to Support Key Efficacy Studies for ABI-2280 including Phase 2 Trial in High-Grade Cervical Intraepithelial Neoplasia (CIN 2,3) and Exploratory Study as Treatment for High-Risk HPV Infections Antiva Biosciences, Inc. biopharmaceutical company developing novel, topical therapeutics for the treatment of …

Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)

Alyssia Watkin Portfolio News, Cyrano Therapeutics, Main Page

Currently no FDA-approved therapy for this serious condition Initiation of Phase 2 clinical trial expected to occur in Q2 2023 Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and …

Lumira Ventures Participates In The Closing of PIC Therapeutics $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer

Alyssia Watkin PIC Therapeutics, Portfolio News, Main Page

Financing Round Led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute and existing investors Advent Life Sciences and Belinda Termeer Therapy development focused on addressing a fundamental mechanism in cancer-driving oncogenes October 19, 2022 – PIC Therapeutics, Inc., …

DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging

Alyssia Watkin DAMONA Pharmaceuticals, Portfolio News, Main Page

TORONTO, Ontario, September 26, 2022 — DAMONA Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging. The …

X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months

Alyssia Watkin Portfolio News, X4 Pharmaceuticals, Main Page

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4 targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggregate of 50,925,365 shares …

Corvia Medical Closed $54 Million Financing to Support Planned Confirmatory Trial of the Corvia® Atrial Shunt

Alyssia Watkin Portfolio News, Corvia Medical, Main Page

Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, Mass., June 9, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing …

XyloCor Therapeutics Presents Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina

Alyssia Watkin Portfolio News, Xylocor Therapeutics, Main Page

Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study Preliminary efficacy data highlight XC001 …